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Summary
Background: Patients with pulmonary tuberculosis are likely to develop pulmonary
impairment after tuberculosis (PIAT). The stability of PIAT and the relationship of
PIAT to the duration of delay in tuberculosis diagnosis and treatment have not been
fully characterized.
Methods: We performed serial pulmonary function tests (PFTs) in a cohort treated
for pulmonary tuberculosis after 20 weeks of tuberculosis therapy and again on or
after treatment completion to determine the stability of PIAT. PFTs were compared
with the duration of delay in tuberculosis diagnosis and treatment, as well as other
demographic variables.
Results: The median duration between the ﬁrst and second tests was 15 (interquar-
tile range 9—34) weeks. Themean change in FVCwas −0.02 l (95% conﬁdence interval
[CI] −0.09, 0.06), and the % predicted was −0.02 (95% CI −2.17, 2.12). FEV1 changes
were 0 l (95% CI −0.05, 0.06), and the % predicted was −0.11 (95% CI −1.82, 1.60).
PIAT was not related to the duration of delay in tuberculosis diagnosis or treatment,
age or smoking.
∗ Corresponding author at: Tarrant County Public Health Department, 1101 South Main Street, Fort Worth, TX 76102,
United States. Tel.: +1 81 7 321 4937; fax: +1 81 7 321 4920.
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uberculosis is a common disease, with 9.4 mil-
ion new cases and 1.3 million deaths reported
orldwide in 2009 [1]. In countries with low tuber-
ulosis burdens, the incidence of tuberculosis is
radually declining [2]. Many patients with pul-
onary tuberculosis undergo anatomical changes
econdary to the illness, such as parenchymal struc-
ural damage including bronchovascular distortion,
ronchiectasis, emphysematous and ﬁbrotic band
ormations, and other well-described histologic and
natomic changes [3]. These anatomical changes
esult in radiographic and functional alterations
hat may remain after microbiologic cure and may
e even more prevalent in patients with treated
ultidrug resistant tuberculosis (TB) [4—11]. Pul-
onary impairment after TB (PIAT), which is
resumably a result of these anatomical changes,
as been shown to be common in patients who have
ompleted at least 20 weeks of tuberculosis treat-
ent [9]. The stability of these changes has not
een fully characterized. Currently, further evalua-
ion after the completion of tuberculosis treatment
s not recommended [12]. Additional evaluation is
nly recommended for patients in whom recurrence
r relapse is suspected, not for surveillance for
hronic sequelae related to TB [12].
Pulmonary function tests are used routinely to
bjectively assess lung function and determine
ung impairment [13,15,16]. Previous studies have
hown that individuals with pulmonary tuberculosis
requently have pulmonary impairment with varied
atterns and severity [4—11]. If pulmonary impair-
ent after tuberculosis was permanent, this would
rovide additional support for strategies to prevent
B, routine testing for impairment after the com-
letion of TB treatment and treatments to mitigate
IAT. Current evidence does not clearly estab-
ish the stability of pulmonary impairment changes
ver time in successfully treated patients. We con-
ucted a prospective study of pulmonary function in
atients treated for culture-conﬁrmed pulmonary
uberculosis using universal directly observed ther-
py (DOT) to determine the stability of PIAT.
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sociated with the duration of delay in tuberculosis diag-
not signiﬁcantly change during follow-up. These data
individuals, the completion of tuberculosis treatment is
f their tuberculosis illness.
d on behalf of King Saud Bin Abdulaziz University for
served.
ethods
tudy population and procedures
ubjects in this study were part of a previ-
usly reported study that measured pulmonary
mpairment after tuberculosis treatment in Tarrant
ounty, Texas [9]. The study cohort consisted of all
nown patients with culture-conﬁrmed tuberculosis
ho had performed at least two PFTs and com-
leted at least 20 weeks of treatment at the time
f their initial PFT in Tarrant County between June
005 and September 2007. According to Texas state
tatute, all persons suspected of having tuberculo-
is must be reported to the local health authority.
n Tarrant County, those persons suspected of hav-
ng tuberculosis are treated by the Division of
uberculosis Elimination at Tarrant County Public
ealth, with universal directly observed therapy
DOT) [14]. As part of the initial encounter, those
ndividuals undergo a standardized evaluation that
ncludes patients’ estimate of the onset of ill-
ess [14]. Patients seen between June 2005 and
eptember 2007 with culture-conﬁrmed pulmonary
uberculosis who had completed a minimum of 20
eeks of tuberculosis treatment were recruited to
his study of pulmonary impairment. Study eval-
ations were incorporated into clinical care visits
or patient convenience. Evaluations included pul-
onary function tests (PFTs) and a standardized
uestionnaire of demographic and occupational
nformation, including exposure to lung irritants,
.g. silica dust, cigarette and biomass smoke and
tandard medical history. Smoking status was cat-
gorized based on lifetime cigarettes smoked in
ack-years: never (0), mild (<30 pack-years) and
eavy (>30 pack-years). The delay in TB diagno-
is and treatment was measured as the length
f time the patient was symptomatic prior to
eceiving TB treatment. Participants were asked
o repeat the procedure at least four weeks
fter the initial test. Those with asthma, COPD,
r a history of bronchodilator treatment per-
ormed PFTs after albuterol nebulization. Children
ess than 12 years old were excluded from the
tudy.
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PFTs were conducted according to the Amer-
ican Thoracic Society recommendations for sub-
ject maneuvers, techniques and quality control
using the Spirotouch® Spirometry System (num-
ber 086578), which was calibrated daily before
use (Spacelabs Burdick, Inc., WI, USA) [13,15].
PFTs were performed sitting or standing accord-
ing to patient preference and without nose clips.
An acceptable maneuver comprised three tests
that were reproducible with values within 5% of
each other. The best of the three values was
used for comparisons. When the variation was
greater than 5%, the best of eight tests was
selected. Forced vital capacity (FVC), forced expi-
ratory volume in 1 s (FEV1), the FEV1:FVC ratio and
the respective % predicted values were the out-
come variables. Enright’s interpretive algorithms
and prediction tables were used to determine
restrictive or obstructive patterns [13]. FEV1≥ 80%,
FVC≥ 80% and FEV1/FVC > 70% of predicted were
considered normal [14]. FEV1 values >60% but <80%
were considered mild PIAT and values 41—59% were
considered moderate PIAT. FEV1 values <40% were
deﬁned as severe PIAT [9,13,16].
Written informed consent was obtained from all
subjects, and the study was approved by the Institu-
tional Review Board of the University of North Texas
Health Science Center at Fort Worth.
Statistical methods
Data were double entered in a Microsoft Ofﬁce 2003
ACCESS database (Microsoft Corporation, Redmond,
WA 98052, USA). Discrepancies were queried and
corrected. Data were analyzed using SPSS version
12 forWindows (SPSS Inc. 233 S. Wacker Dr, Chicago,
IL 60606-6307, USA) and GraphPad Prism version 5
software (GraphPad Software, La Jolla, CA, USA).
The following variables were included in our
analysis: the age at the time of the ﬁrst test, gen-
der, race, self-reported cigarette smoking, body
mass index, delay in TB diagnosis and treatment,
biomass exposure, history of physician-diagnosed
chronic lung conditions (e.g. asthma, emphysema,
and chronic bronchitis) and time elapsed between
ﬁrst and second PFTs. Differences between the ﬁrst
and second PFT values, including FVC, FEV1 and,
FEF 25—75, were calculated; henceforth, they are
designated FVC, FEV1 and FEF 25—75, respec-
tively. Similar methods were applied to PFT % of
predicted values. Comparisons between the groups
regarding frequencies were made using Fisher’s
exact test or chi squared tests of association.
The Pearson correlation coefﬁcient (r) was used
to evaluate correlations between linear variables.
Although random measurement error does not
t
p
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sually change observed PFTmean; subject fatigue,
cute responses to allergens, diurnal or seasonal
ariation, together with the random measurement
rror can increase PFT variance [17]. The statistic
sed to measure the relative size of this measure-
ent error is the reliability coefﬁcientG. Reliability
oefﬁcient G compares the amount of within-
erson variability to the between-person variability
17,18]. We assessed the reliability of repeated lung
unction tests in these subjects using previously
escribed methods [17].
UnadjustedmeanFVC,FEV1,FEV1/FVC and
FEF 25—75 volumes and their respective % pre-
icted values were calculated. We used the analysis
f covariance to adjust for the effect of age and
he interval between the ﬁrst and second test on
he within-subject FVC, FEV1 and FEF 25—75
olume values. Scatter plots and regression equa-
ions of changes in % predicted FEV1/FVC over time
ere also performed, and they were stratiﬁed by
moking and severity of pulmonary impairment at
he end of therapy. The resulting mean regression
lopes were tested for a signiﬁcant difference from
ero at an alpha level of 0.05.
esults
f the original cohort of 166 subjects with culture-
onﬁrmed pulmonary tuberculosis who had PFTs,
23 (74%) had the second PFT and were included
n this analysis. The demographic variables of the
ncluded subjects did not signiﬁcantly differ from
hose with a single PFT. The study population was
acially heterogeneous with Caucasian and Hispanic
ubjects composing 54% of the sample (data not
hown). The mean age was 48 years (standard
eviation [SD] = 16) years, and the majority (71%)
ere men. Only 15 (12%) reported a prior physi-
ian diagnosis of any other chronic lung disease. All
ubjects were treated following standard ATS/CDC
ecommendations for anti-TB regimens [12]. Fif-
een (12%) patients demonstrated resistance to at
east one of the ﬁrst-line anti-TB drugs used, and
nly two (2%) of these patients exhibited multidrug
esistance (i.e., resistance to both isoniazid and
ifampin). None of the patients received surgical
reatments.
More than half (70 out of 123) of the subjects
emonstrated some degree of pulmonary impair-
ent, including 11 (9%) with severe impairment
i.e., <50% of predicted FVC). An obstructive pat-
ern was observed in 27 (22%) subjects, a restrictive
attern was observed in 27 (16%) subjects, and a
ombined pattern was observed in 17 (14%) sub-
ects. The prevalence of HIV was 13%. The median
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uration between the ﬁrst and second tests was
5 (interquartile range [IR] 9—34) weeks. The PFTs
ere reproducible in 242/246 (98%) of the tests
erformed.
The PFT data including FVC, FEV1 and
FEV1/FVC were normally distributed. No signiﬁ-
ant within-person PFT changes were noted during
he observation period (Tables 1—3 and Figs. 1 and
). ThemeanFVCwas −0.02 l (95% CI −0.09, 0.06)
95% conﬁdence interval [CI]) and the % predicted
as −0.02 (95% CI −2.17, 2.12). The mean FEV1
as 0 l (95% CI −0.05, 0.06), and the % predicted
as −0.11 (95% CI −1.82, 1.60). The mid-ﬂow rates
ere not statistically different (Table 1 and Fig. 1).
he reliability coefﬁcient G was 0.93 (95% CI 0.75,
.00) for FVC and 0.95 (95% CI 0.77, 1.00) for FEV1.
The unadjusted within-subject mean FVC and
FEV1 for all variables speciﬁed above are shown
n Table 2. The mean change in forced vital capac-
ty (FVC) was not statistically signiﬁcant; −0.02
0.04) (standard error [SE]) in men and 0.01 l (0.04)
n women (Figs. 1 and 2 and Table 2). Similarly,
he mean % predicted FVC changes were not sig-
iﬁcant: −0.15 (1.40) for men and 0.28 (1.54)%
or women. The mean (SE) FVC change in sub-
ects who were moderately impaired at the ﬁrst
est was −0.14 l (0.16), and in heavy smokers (>30
ack-years), this value was −0.13 l (0.06) (Table 2).
here were no signiﬁcant changes in either FVC or
EV1 for other variables tested, including country
f birth, race, weight (BMI), or presence of prior
hronic diseases (Table 3). FEF 25—75% and % pre-
icted FEV1/FVC changes were similarly unchanged
data not shown). Similarly, changes in mean PFT
alues as a percentage of the normal predicted
alues were low and not clinically or statistically
igniﬁcant (Table 3).
Table 3 shows trends and cumulative PFT
hanges. The adjusted mean FVC and FEV1
tratiﬁed by impairment status at the ﬁrst PFT and
elf-reported smoking status, controlled for body
ass index, duration between ﬁrst and second PFT
nd age. Across all impairment levels, PFT improve-
ents were greater in non-smokers than smokers,
ut these improvements did not reach statistical
igniﬁcance. Furthermore, the mean FVC, FEV1
nd, FEF 25—75 values did not signiﬁcantly differ
ccording to smoking status (data not shown).
The delay in TB diagnosis and treatment was
.9 (IR 3.9—17.6) weeks. The correlation between
he delay in TB diagnosis and treatment and
FEV1/FVC was not signiﬁcant (r = 0.03 p = 0.7659).n addition, the mean delay in TB diagnosis
nd treatment in subjects with normal PFTs was
ot signiﬁcantly different from impaired subjects
p = 0.339). The delay in TB diagnosis and treatment
l
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lso did not correlate with the interval between PFT
ests (data not shown). There was no association
etween drug resistance and pulmonary impair-
ent (p = 0.785). Additionally, the median FVC
nd FEV1 values of those with drug susceptible
B and those with any drug resistance were similar
p = 0.336 and p = 0.234, respectively).
PFTs did not signiﬁcantly change over time
ccording to the subjects’ initial impairment status
Supplementary Fig. 2, panels A and B). In addition,
moking status or volume of cigarettes smoked did
ot signiﬁcantly correlate with PFT changes over-
ime (Supplementary Fig. 2, panel C).
iscussion
e studied the effect of time and additional tuber-
ulosis chemotherapy on the stability of pulmonary
mpairment in a cohort with culture-conﬁrmed pul-
onary tuberculosis receiving universal directly
bserved therapy (DOT) [14]. PFT parameter
hanges were minimal and statistically insigniﬁcant
Table 1 and Fig. 1). Recent data from large clini-
al trials suggest that an absolute change greater
han 225ml is a clinically useful benchmark for
etecting changes in FEV1 in an individual patient,
rrespective of the baseline level of FEV1 [25].
lternatively, a greater than 10% change and an
bsolute change of at least 150ml would signify
linical improvement [13,15,26,27]. Taken together
ith recommendations for interpreting changes in
ulmonary function, these data show that pul-
onary impairments are stable in subjects after
0 weeks of tuberculosis therapy, suggesting that
hese changes may be permanent.
Pulmonary impairment from TB is incompletely
haracterized in subjects treated with short-course
nti-tuberculosis therapy, including DOT [4,6,8,9].
n a Canadian study of 25 newly diagnosed TB
atients treated with DOT that correlated PFTs
ith computerized lung tomography, four subjects
16%) had impaired lung function and one sub-
ect had severe impairment (an FEV1 of <1.0 l)
4]. That study found that pulmonary function
mpairment identiﬁed at the time of tuberculo-
is diagnosis was not signiﬁcantly changed after
ix months of therapy [4]. A Latin American study
xamining impairment associated with tuberculosis
rom a population view found that persons report-
ng a prior TB diagnosis were more than twice as
ikely to have airﬂow obstruction [8]. In a retro-
pective study of South African men sufﬁciently ﬁt
o be employed as gold miners, pulmonary impair-
ent was found to be stable 12 months after
248 M. Vecino et al.
Table 1 Overall study subject characteristics; within-person meanFVC,FEV1, FEV1/FVC andFEF 25—75; and
differences in the respective % predicted values in subjects completing both pulmonary function tests (n = 123).
Average within-person difference
Mean (95% CI) p-Value G (95% CI)
Age 48.10 (45.24, 50.95)
Body mass index 23.45 (22.54, 24.36)
Duration untreated (weeks)b 8.9 (3.9, 17.6)
FVC (l)a −0.02 (−0.09, 0.06) 0.622 0.93 (0.75, 1.00)
FEV1 (l) 0 (−0.05, 0.06) 0.930 0.95 (0.77, 1.00)
FEF 25—75 (l) −0.04 (−0.15, 0.08) 0.527 0.88 (0.70, 1.00)
% predicted FVC −0.02 (−2.17, 2.12) 0.982 0.85 (0.67, 1.00)
% predicted FEV1 −0.11 (−1.82, 1.60) 0.895 0.93 (0.75, 1.00)
% predicted FEV1/FVC 0.63 (−0.85, 2.10) 0.403 0.81 (0.75, 1.00)
% predicted FEF 25—75 −0.47 (−4.72, 3.77) 0.826 0.82 (0.65, 0.99)
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; FEF 25—75, mid forced expiratory ﬂow; CI, conﬁdence interval;
G reliability coefﬁcient; FVC = 1st FVC—2nd FVC, FEV1 = 1st FEV1—2nd FEV1.
a Based on Student T-test, alpha signiﬁcant at 0.05.
b Median (inter-quartile range [IR]) in weeks.
Table 2 Within-subject mean (standard error of the mean [SEM]) changes in forced vital capacity (FVC) and
forced expiratory volume in 1 s (FEV1) and corresponding changes in % predicted values in subjects with a second
pulmonary function test (PFT) (n = 123).
FVC (l) FEV1 (l)
Mean (SEM) Mean (SEM)
Gender Female 0.01 (0.04) 0.04 (0.04)
Male −0.02 (0.05) −0.01 (0.03)
Impairment status at ﬁrst PFT test None 0.06 (0.05) 0.10 (0.04)a
Mild −0.06 (0.07) −0.07 (0.05)
Moderate −0.14 (0.16) −0.09 (0.10)
Severe −0.08 (0.13) −0.03 (0.07)
Diagnosis PTB only −0.02 (0.04) 0.02 (0.03)
PTB and EPTB 0 (0.07) −0.10 (0.11)
Country of birth Foreign born −0.01 (0.05) 0.04 (0.04)
USA born −0.03 (0.06) −0.03 (0.04)
Presence of chronic lung disease Yes −0.09 (0.15) −0.02 (0.09)
No −0.01 (0.04) 0.01 (.0.03)
Biomass exposure No biomass exposure 0 (0.06) 0 (0.03)
Some biomass exposure 0.01 (0.07) 0.06 (0.05)
Race Caucasian −0.05 (0.05) −0.05 (0.06)
Hispanic 0.01 (0.08) −0.01 (0.04)
African-American −0.07 (0.09) −0.02 (0.06)
AIAO 0.03 (0.08) 0.08 (0.06)
BMI Underweight (<18.50) −0.10 (0.08) 0.02 (0.06)
Normal (18.5—24.99) −0.02 (0.05) 0 (0.03)
Overweight (25.00—29.99) 0 (0.11) 0.03 (0.08)
Obese (30.00) 0.06 (0.16) −0.09 (0.19)
Smoke volume Never smokers −0.02 (0.08) −0.01 (0.06)
Mild smokers (<30 pack-years) 0.02 (0.05) 0.02 (0.04)
Heavy smokers (>30 pack-years) −0.13 (0.06) −0.03 (0.05)
Duration between 1st and 2nd test (weeks) <9 weeks −0.01 (0.06) 0 (0.06)
9—34 weeks −0.02 (0.05) 0.03 (0.04)
>34 weeks −0.04 (0.10) −0.04 (0.05)
AIAO, Asian, Indian, African and Other racial groups; USA, United States of America; PTB, pulmonary tuberculosis; EPTB, extra
pulmonary tuberculosis; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; FEF, mid forced expiratory ﬂow; BMI,
body mass index.
FVC = 1st FVC—2nd FVC, FEV1 = 1st FEV1—2nd FEV1.
a Change statistically signiﬁcant at alpha 5%.
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Table 3 Within-subject adjusted means forFEV1 andFVC in liters, stratiﬁed by smoking status and impairment
status at the ﬁrst pulmonary function test.
Smoking Impairment N (%) Mean FEV1 (95% CI) Mean FVC (95% CI)
None None 18 (15) 0.21 (0.06, 0.35)* 0.13 (−0.07, 0.33)
Mild 18 (15) −0.06 (−0.20, 0.08) 0.05 (−0.15, 0.25)
Moderate 4 (3) −0.29 (−0.58, 0.01) −0.35 (−0.77, 0.07)
Severe 5 (4) −0.16 (−0.43, 0.11) −0.29 (−0.67, 0.09)
Smoker None 35 (28) 0.06 (−0.04, 0.16) 0.03 (−0.11, 0.17)
Mild 27 (22) −0.08 (−0.19, 0.04) −0.13 (−0.30, 0.03)
Moderate 10 (8) −0.04 (−0.23, 0.14) −0.07 (−0.33, 0.20)
Severe 6 (5) 0 (−0.25, 0.26) 0.07 (−0.29, 0.43)
Covariates appearing in the model are evaluated using the following values: Duration between the 1st and 2nd test (weeks) = 24.76,
body mass index = 23.4531, age (years) = 48.10; FVC = forced vital capacity, FEV1 = forced expiratory volume after 1 s. FVC = 1st
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* Statistically signiﬁcant at alpha = 5%.
he TB diagnosis [7]. In another study from South
frica, pulmonary impairment observed in hospi-
alized TB patients at the beginning of treatment
mproved modestly but still persisted after six
onths of treatment [19]. A recent cross-sectional
tudy of MDR-TB patients from India revealed that
lmost all (45/47 or 96%) had abnormal PFT values,
nd 98% had residual radiological sequelae despite
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herapy; these ﬁndings suggest that PIAT is worse in
atients with drug-resistant TB [11]. The data from
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eneous cohort of tuberculosis patients treated
ith DOT were insufﬁcient to establish a rela-
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that impairment identiﬁed after 20 weeks of treat-
ment remained stable during an average of 15
additional weeks of observation. These ﬁndings
support a recent report by the TAMI group, from
Taipei, Taiwan, in which pulmonary impairment
was described in a retrospective cohort of 115
patients successfully treated for mycobacterial dis-
eases including TB ([10]; also see scatter plot in
Supplementary Fig. 2). In that study, a series of
U-shaped and inverted U-shaped changes in both
FEV1 and FVC, with a nadir 18 months after treat-
ment, suggested that despite successful treatment
residual impairments persisted. Taken together, the
results from previous studies [4,7,8,10,11,19] and
the present study of patients receiving univer-
sal DOT demonstrate that, reducing PIAT requires
tuberculosis prevention, not earlier tuberculosis
treatment.
The delay in TB diagnosis and treatment includes
patient-level delays in seeking health care and
clinician-level delays in diagnosis and treatment of
TB [12,28,29]. It is intuitive that delayed tubercu-
losis treatment would be associated with poorer
clinical outcomes, and there is some support for
this hypothesis in the literature [12,28]. However,
data from other studies conﬂict with this sugges-
tion [29]. Our data demonstrate that persons with
longer delays in TB diagnosis and treatment are not
more likely to have pulmonary impairment. There
are several possible explanations for this ﬁnding.
Individuals who develop impairment may be more
ill and seek medical attention earlier. Alternatively,
they may have more classic TB radiographic ﬁnd-
ings and therefore receive the correct diagnosis
sooner. It is also possible that the changes underly-
ing PIAT occur early in the disease process, before
treatment initiation. While early diagnosis is impor-
tant to reduce the transmission of TB [12,28,29],
our ﬁndings suggest that earlier diagnosis may not
reduce PIAT.
Serious illnesses that result in clinically impor-
tant impairment may predict subsequent pre-
mature mortality. For example, meningeal and
pericardial tuberculosis have recently been associ-
ated with premature mortality [20—22]. Pulmonary
impairment is a predictor of premature mortal-
ity in the general population and among patients
with selected cardiovascular risk factors [22—25].
In our study, approximately one in ten patients
completing TB therapy had severe impairment
(less than half of their lung function; FEV1 <40%
and FVC <50%) that remained stable during the
study period, regardless of age, smoking status,
volume smoked or degree of initial impairment
(Table 3 and Supplementary Fig. 2) [9]. Patients
with moderate and severe impairment at initial
r
d
v
aM. Vecino et al.
esting did not demonstrate PFT improvements
fter follow-up. On the contrary, patients with
ormal initial pulmonary function had a slight
mprovement in their PFTs (r = 0.26; p = 0.087)
Supplementary Fig. 2, panel B). Impaired subjects
id not demonstrate signiﬁcant pulmonary func-
ion changes. Regardless, the discordance in these
bservations is important and may suggest predis-
ositions to lung damage in certain populations. We
ropose that the anatomical changes that result
n PIAT occur early in the disease process, con-
idering that we observed no correlation between
iagnostic delay and abnormal PFTs. It bears not-
ng that these patients were treated with DOT
ccording to established and recommended guide-
ines [14]. Furthermore, non-reversible impairment
as apparent in non-smokers, mild smokers, and
eavy smokers (Supplementary Fig. 2, panel C).
he main risk factors commonly associated with
ecline in pulmonary function (i.e., smoking, delay
n treatment or age) did not signiﬁcantly impact
he ﬁndings, suggesting that pulmonary impair-
ent is inherently inﬂuenced by other host or
athogen factors. Taken together, we infer from
hese data that pulmonary impairment in success-
ully treated TB patients could be a risk factor for
ong-term disability and probably premature mor-
ality.
Based on American Medical Association crite-
ia for pulmonary impairment, 57% of patients
n this cohort had PIAT. The PIAT was moder-
te in severity in 11%, while 9% had severe
mpairment (Table 3) [16]. PIAT could poten-
ially be prevented at three levels. Primary
revention could be achieved by preventing TB
nfection. Secondary prevention would focus on
reventing persons with LTBI from developing
uberculosis. Tertiary prevention would rely on
eveloping targeted treatments for persons with
ctive tuberculosis to mitigate lung damage.
t has been suggested that immunomodulatory
herapy for TB pericarditis, multidrug resistant
uberculosis and TB meningitis may reduce the
everity of postdisease sequelae [20,21,30—32].
owever, clinical trial data has produced con-
icting results regarding the speciﬁc beneﬁts
f immunomodulatory therapy regarding differ-
nt outcomes [12,31]. In the absence of an
ffective vaccine, immunomodulatory or optimized
herapy against TB, public health measures that
revent infection and progression to TB disease
re the only currently available measures to
educe long-term disability from TB. These data
emonstrate that the prevention of PIAT is a pre-
iously underappreciated beneﬁt to TB control
ctivities.
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[vidence for chronic lung impairment in patients tr
These data have several limitations. Interpreting
erial PFT changes in non-diseased or non-impaired
ubjects is prone to error, as test variability
sually exceeds the expected annual decline in PFTs
15,17,27,33]. Forty-three percent of our cohort
ad normal PFTs, and the follow-up period was
elatively short. When we stratiﬁed absolute PFT
hanges over time by degree of impairment at
he ﬁrst test or by smoking volume, however, no
igniﬁcant changes were observed (Table 3 and
upplementary Fig. 2). We therefore have no rea-
on to suspect that excluding those who did not
erform both tests would change our ﬁndings. Fur-
hermore, although the study was limited to a
ingle geographic area, the racially and ethnically
eterogeneous study population suggests that our
onclusions are generalizable.
In summary, we found that the duration of tuber-
ulosis symptoms prior to the institution of TB
reatment did not correlate with the degree of
mpairment. Additionally, pulmonary impairment
hat was present after 20 weeks of DOT for tubercu-
osis did not signiﬁcantly change after an additional
5 weeks of observation. These data suggest that
mpairment, when present, may be permanent. It
s important for both clinicians providing ongoing
are for patients with a history of TB and policy-
akers providing tuberculosis control guidelines to
ecognize that the completion of tuberculosis ther-
py is insufﬁcient to prevent chronic pulmonary
mpairment in many patients. Additionally, the
mpairment is frequently severe enough to result
n disability and possibly even premature death.
aken together, the results from previous studies
4,7,8,10,11,19] and the present study of patients
eceiving universal DOT demonstrate that, for many
ndividuals, the completion of tuberculosis therapy
s only the beginning of TB illness.
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